Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia

Using ex vivo drug screening of primary patient specimens, we identified the combination of the p38 MAPK inhibitor doramapimod (DORA) with the BCL2 inhibitor venetoclax (VEN) as demonstrating broad, enhanced efficacy compared with each single agent across 335 acute myeloid leukemia (AML) patient sam...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Long, Nicola, Bottomly, Daniel, Nikolova, Olga, Druker, Brian J., McWeeney, Shannon K., Chang, Bill H., Tyner, Jeffrey W., Agarwal, Anupriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131911/
https://www.ncbi.nlm.nih.gov/pubmed/35078224
http://dx.doi.org/10.1182/bloodadvances.2021006307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131911/
https://www.ncbi.nlm.nih.gov/pubmed/35078224
http://dx.doi.org/10.1182/bloodadvances.2021006307

Ejemplares similares